No limit to the benefits of exercise in reducing the risk of cardiovascular disease

A new study led by the University of Oxford on over 90,000 participants shows that there is no upper threshold to the benefits of exercise in reducing the risk of cardiovascular disease – ‘every move counts towards better cardiovascular health.’

Accurate predictions of ovarian cancer outcome possible with new classification system

The new, Oxford-developed method for subtyping ovarian cancer has been validated in a recent collaboration between the University of Oxford and Imperial College London. Dubbed the ‘Oxford Classic’, researchers have demonstrated that it enables the accurate prediction of patient disease outcome, as well as the development of new targeted cancer therapies.

COVID-19 transmission chains in the UK accurately traced using genomic epidemiology

A team of scientists, led by researchers from the Universities of Oxford and Edinburgh, has analysed the first wave of the COVID-19 outbreak in the UK and produced the most fine-scaled and comprehensive genomic analysis of transmission of any epidemic to date.

A healthy heart may help delay or prevent dementia

New study shows targeting arterial stiffening earlier in a person’s lifespan could provide cognitive benefits in older age and may help to delay the onset of dementia.

UK National Health Service begins rollout of Oxford coronavirus vaccine

At 7.30 am today, dialysis patient Brian Pinker became the very first person to be vaccinated as part of the UK’s rollout of the Oxford / AstraZeneca coronavirus vaccine, ChAdOx1 nCoV-19, with patients at the Oxford University NHS Hospitals Trust becoming the first to receive this life-saving vaccine.

New Year's Honours 2021

Members of the University have been recognised in the New Year's Honours list for 2021.

National COVID-19 Infections Survey reveals changes to pandemic over time

Data from the National COVID-19 Infection Survey, done in partnership between the University of Oxford, the Office of National Statistics, Public Health England, University of Manchester and the Wellcome Trust, has revealed detailed characteristics of England’s coronavirus pandemic, including which factors have contributed most to case numbers over different phases and the prevalence of asymptomatic infections.

University of Oxford awarded major European Research Council funding

European Research Council grants worth more than €16.3 million have today been awarded to eight University of Oxford researchers for a range of cutting-edge projects.

Researchers find very high rates of Covid-19 in the Brazilian Amazon

By testing approximately 1,000 blood donation samples each month in in the Brazilian cities of São Paulo and Manaus, an international team of researchers have shown that, while both cities have experienced large epidemics with high mortality, as much as three-quarters of the population in Manaus was infected between March and October, and a third of the population in São Paulo.

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

Our vaccine work is progressing quickly. To ensure you have the latest information or to find out more about the trial, please visit the Oxford COVID-19 vaccine web hub or visit the COVID-19 trial website. - Researchers show overall vaccine efficacy of 70.4% from a pooled analysis of two-dose regimen - No hospitalisations or severe disease observed in the vaccinated groups from three weeks after first dose - Efficacy results are based on data taken from 11,636 volunteers across the United Kingdom and Brazil - Data are first Phase 3 trial results of a coronavirus vaccine to be published in peer-review literature

Philharmonic Orchestra film special tribute concert for the Oxford vaccine team

A special concert to say thank you and pay tribute to the achievements of the Oxford vaccine team has been recorded at the Sheldonian Theatre for a film screening in time for Christmas

$10 million gift for new Nanoscience Institute in Oxford

A new institute for nanoscience research is to open in Oxford thanks to a $10 million gift from The Kavli Foundation.

Oxford University breakthrough on global COVID-19 vaccine

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

Viruses shown to evolve as a result of different immune responses in different ethnic populations

New research into the HIV-1 virus has shed light on an important factor in the evolution of viruses, which is likely also to affect SARS-CoV-2 (the virus which causes COVID-19). This new insight could have important implications for vaccine development.

Oxford ramps up COVID-19 testing capability

The University of Oxford has joined forces with Thermo Fisher Scientific, the world leader in serving science, to ramp up the university’s capacity to deliver COVID-19 testing data.

New partnership with King Abdulaziz University aims to revolutionise drug discovery using artificial intelligence

The University of Oxford and King Abdulaziz University (KAU) have partnered to create a new Centre for Artificial Intelligence and Precision Medicine.

Comparison of five tests used to detect COVID-19 antibodies shows Siemens and Oxford assays met regulatory targets

New research shows that, in a head-to-head comparison of five tests used to detect COVID-19 antibodies (known as ‘immunoassays’), an assay manufactured by Siemens and one developed by an academic partnership led by the University of Oxford had the most accurate results. The study is published in The Lancet Infectious Diseases.

Global consortium launches new study into long-term effects of COVID-19

The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC), based at Oxford University, in collaboration with Dr Janet Scott, of the MRC-University of Glasgow’s Centre for Virus Research, has launched a longitudinal observational study to measure prevalence and risk factors of long-term health and psychosocial consequences of COVID-19. The researchers are inviting hospitals and healthcare sites worldwide to join this new study.

Load More